EMA Authorised: Neoatricon (dopamine hydrochloride;Dopamine) — BrePco Biopharma Limited

View source ↗

Summary

The European Medicines Agency authorised Neoatricon, a dopamine hydrochloride product, for the treatment of hypotension in the European Union, marketed by BrePc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypotension

Drugs mentioned

• Neoatricon (dopamine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Hypotension. MAH: BrePco Biopharma Limited. Decision date: 27/06/2025